Improving the management of pain from advanced cancer in the community: study protocol for a pragmatic multicentre randomised controlled trial

Matthew J Allsop, Alexandra Wright-Hughes, Kath Black, Suzanne Hartley, Marie Fletcher, Lucy E Ziegler, Bridgette M Bewick, David Meads, Nicholas D Hughes, S José Closs, Claire Hulme, Sally Taylor, Kate Flemming, Julia Hackett, John L O’Dwyer, Julia M Brown, Michael I Bennett

ABSTRACT

Introduction For patients with advanced cancer, research shows that pain is frequent, burdensome and undertreated. Evidence-based approaches to support cancer pain management have been developed but have not been implemented within the context of the UK National Health Service. This protocol is for a pragmatic multicentre randomised controlled trial (RCT) to assess feasibility, acceptability, effectiveness and cost-effectiveness for a multicomponent intervention for pain management in patients with advanced cancer.

Methods and analysis This trial will assess the feasibility of implementation and uptake of evidence-based interventions, developed and piloted as part of the Improving the Management of Pain from Advanced Cancer in the Community Programme grant, into routine clinical practice and determine whether there are potential differences with respect to patient-rated pain, patient knowledge and experience, healthcare use, quality of life and cost-effectiveness. 160 patients will receive either the intervention (usual care plus supported self-management) delivered within the oncology clinic and palliative care services by locally assigned community palliative care nurses, consisting of a self-management educational intervention and eHealth intervention for routine pain assessment and monitoring; or usual care. The primary outcomes are to assess implementation and uptake of the interventions, and differences in terms of pain severity. Secondary outcomes include pain interference, participant pain knowledge and experience, and cost-effectiveness. Outcome assessment will be blinded and patient-reported outcome measures collected via post at 6 and 12 weeks following randomisation.

Ethics and dissemination This RCT has the potential to significantly influence National Health Service delivery to community-based patients with pain from advanced cancer. We aim to provide definitive evidence of whether two simple interventions delivered by community palliative care nurse in palliative care that support-self-management are clinically effective and cost-effective additions to standard community palliative care.

Trial registration number ISRCTN18281271; Pre-results.

INTRODUCTION

Each year in the UK, 163000 people die from cancer. For patients with cancer, research shows that pain is frequent, burdensome and undertreated. Over two-thirds (66.4%) of these patients will experience pain during advanced, metastatic or terminal stages of their cancer. Many patients with cancer spend their last 6 months of life living in the community, typically at home, though many are admitted as inpatients nearer to death. Barriers to good pain control include inadequate support and patient education, poor assessment and communication, and lack of access to an adequate prescription and timely analgesia. A range of approaches have been developed that seek to improve the management of pain in patients with advanced cancer but have not been implemented within the...
context of the National Health Service (NHS) in the UK. Three emerging approaches that address key barriers to pain management for patients with advanced cancer are outlined, including referral to specialist palliative care, self-management of pain and analgesia, and routine monitoring of pain.

**Specialist palliative care**

Specialist palliative care aims to relieve suffering and improve quality of life for people with advanced diseases, such as cancer, who are facing death. For patients with advanced cancer, several randomised controlled trials (RCTs)\(^{10-14}\) have shown that early access to palliative care can improve symptoms, reduce acute hospital admissions, minimise aggressive cancer treatments and enable patients to make choices about their end-of-life care, including exercising the choice to die at home. Interventions in these trials varied, but common characteristics included assessment and several follow-up consultations by specialist palliative care teams over a period of 2–5 months. Where reported, patients were recruited and received these interventions about 6 to 14 months before their death.\(^{10-14}\) Collectively, these data suggest that a dose of three to four palliative care contacts applied about 6 months before death is associated with better end-of-life care. The trials from which this evidence is derived were based in North America, and the studies vary widely in their definition of what constitutes palliative care services and who provides them. These limitations have prevented direct translation and implementation of this evidence within the context of the UK NHS.

**Supporting self-management of pain and analgesia**

Pain for patients with advanced cancer is a complex and dynamic experience.\(^{15}\) Poor knowledge and fearful attitudes within patients towards cancer pain and analgesia are associated with reluctance to commence opioids, reduced medication adherence and higher pain intensity.\(^{24\text{--}26}\) Providing information to patients with cancer pain and addressing concerns regarding pain and analgesia are effective interventions that support self-management and lead to improvements in pain outcomes.\(^{18\text{--}22}\) While evidence supports the use of self-management approaches, there remains uncertainty on the optimum dose and components of a self-management intervention, and how best to implement these in routine practice.

**Routine monitoring of pain**

Assessing pain and presenting data to physicians prior to consultation, who then use it within discussions, significantly improves pain outcomes and quality of life for patients.\(^{23}\) Assessment alone without ensuring that this is seen by prescribing clinicians does not lead to improvements in pain,\(^{24}\) highlighting the need for interventions to alert clinicians to patients’ symptoms. Two large RCTs, one conducted in the USA\(^{25}\) and one in the Netherlands,\(^{26}\) have demonstrated improvements in cancer pain when combinations of interventions have been evaluated. The first compared telephone self-management support from nurses combined with automated symptom monitoring, with usual care. Significant reductions in pain scores were demonstrated over a 12-month period.\(^{25}\) The second combined specialist pain consultation with nurse-led self-management support and compared this with usual care.\(^{26}\) Over an 8-week follow-up period, significant benefits were experienced by intervention patients in pain scores and reduction in interference in daily living from pain. Similar to education self-management approaches, there is uncertainty about the optimum dose, alongside a lack of evidence of implementation in the context of the UK NHS.

**Rationale**

We have developed a complex intervention consisting of three distinct components: (1) referral to community palliative care support, (2) a resource to support self-management of pain and analgesia, and (3) an electronic pain monitoring system. We hypothesise that within oncology (or related) services, screening and referral of community-based patients with pain from advanced cancer to a cancer pain pathway, combined with a package of routine pain assessment and monitoring using an e-health tool, will reduce the extent of pain and psychological distress reported by the patient.

We will undertake a multicentre RCT to assess the acceptability and feasibility of implementation of the complex intervention, its potential cost-effectiveness and impact on pain management.

**METHODS AND ANALYSIS**

This trial is the fourth and final project of a National Institute for Health Research Programme Grant for Applied Research (NIHR PgiAR), which consists of interlinked studies aiming to improve the management of pain from advanced cancer in the community: Improving the Management of Pain from Advanced Cancer in the Community (IMPACCT).

The programme follows the Medical Research Council Framework guidance for the design and evaluation of complex interventions\(^{27}\) and consists of the following component projects:

- To design and test a cancer pain pathway that allows early intervention and promotes self-management.
- To demonstrate the feasibility of routine cancer pain monitoring within the NHS.
- To promote non-medical prescribing and develop the role of community pharmacists.
- To establish the feasibility of delivery of our intervention in routine care, and potential effectiveness on patient outcomes and cost-effectiveness (which this protocol relates to).

**Aims**

The trial aims to assess the feasibility of implementation and uptake of evidence-based interventions, developed
and piloted as part of the IMPACCT NIHR PGfAR, into routine clinical practice and determine whether there are potential differences with respect to (1) patient-rated pain, (2) patient pain knowledge and experience, (3) healthcare use, (4) quality of life and (5) cost-effectiveness.

Our intervention, combining usual care and supported self-management, including an educational resource and pain monitoring, aims:

► To improve the management of cancer pain for palliative care patients who are living at home.
► To enable patients to more easily access support and advice, communicate their pain, and obtain timely and effective medication.
► To educate patients on tackling cancer pain through an educational intervention.

**Design**

This is a pragmatic multicentre RCT to evaluate the feasibility of delivery and implementation of a supported self-management intervention into routine clinical practice in the UK for patients with cancer, which is active and incurable; and its potential impact on pain management and cost-effectiveness (see [figure 1](#) for a trial flow diagram). Qualitative and cost-effectiveness components are embedded.

We will aim to recruit 160 participants at the point of identification for referral into palliative care and follow-up at 6 and 12 weeks. Participants will be randomised on a 1:1 basis to receive either usual care plus supported self-management, delivered within the oncology clinic and palliative care services by locally assigned community palliative care nurses, or usual care. As part of usual care, all participants will be referred to their local palliative care team for pain management.

**Objectives**

Objectives relate to both the feasibility of delivery and implementation of interventions into routine practice and an assessment of the effectiveness of the intervention:

► Delivery and implementation of the intervention: The primary implementation objective is to evaluate adherence in terms of the uptake and retention rate of each intervention through process evaluation, including qualitative study.
► Potential effectiveness of the intervention: The primary effectiveness objective is to assess the effectiveness of the intervention compared with usual care as measured by pain severity on the Brief Pain Inventory (BPI) 12 weeks after randomisation. Secondary objectives will assess differences at 6 weeks,
patient-rated pain on the 7-point global rating of change in pain, \(^{28}\) healthcare use in each arm, patient’s pain knowledge and experience, patient’s general and cancer-specific quality of life, and cost-effectiveness of the interventions.

### Recruitment, setting and participants

Participants will be identified and recruited in the oncology (or related) clinic by the research nurse, in consultation with the patient’s clinician/treating team. Prior to the start of recruitment into the trial, research centres will be required to have obtained local ethical and management approvals and undertaken training in the intervention and in the trial procedures delivered by the central trial team.

To be included in the trial, participants are required to meet the eligibility criteria described in [Table 1](#). All patients presenting to clinics with a cancer diagnosis of advanced incurable disease will be screened. Data will be recorded anonymously to document reasons for ineligibility or decline in participation to monitor trial uptake and recruitment progress, and representativeness of the trial population.

Patients meeting the eligibility criteria will be approached by the research nurse while they attend the clinic for their standard follow-up care to confirm eligibility and provide verbal and written details about the trial. Patients will be provided with a Participant Information Sheet and given as long as they need to consider participation in the trial, as well as the opportunity to discuss the trial with their family and other healthcare professionals. Patients will then be asked whether they would be willing to take part in the trial and informed consent, and baseline assessments, will be obtained in a location convenient for the participant, at their home or clinic.

### Randomisation and blinding

Following confirmation of eligibility, written informed consent and completion of baseline assessments, participants will be randomised into the trial by the research nurse. Randomisation will be performed centrally via an automated system at the Clinical Trials Research Unit at the University of Leeds. Participants will be randomised on a 1:1 basis to receive either usual care plus supported self-management or usual care, using a computer-generated minimisation programme, incorporating a random element, to ensure treatment groups are well balanced for the following: average pain at baseline on the BPI (4–6, 7–10) and recruiting site. The recruiting team are not involved in subsequent intervention delivery.

### Intervention

Both usual care, and the intervention, usual care plus supported self-management will be delivered within the oncology clinic and palliative care services by locally assigned community palliative care nurses. As part of usual care, all participants will be referred to their local palliative care team for pain management. Supported self-management will consist of an educational intervention ‘Tackling Cancer Pain’ and an e-Health routine pain self-management will consist of an educational intervention ‘Pain Check’, incorporating a random element, to ensure treatment groups are well balanced for the following: average pain at baseline on the BPI (4–6, 7–10) and recruiting site. The participants in the interventions, which will include a demonstration for the participant on how to log on and use PainCheck at the initial visit, and written instructions and a contact for any future queries will be provided. The participants will receive the educational intervention ‘Tackling Cancer Pain’ booklet and DVD from the palliative care team and asked to use it as much and as often as they would like.

### Table 1  Eligibility criteria

<table>
<thead>
<tr>
<th>Eligibility criteria</th>
<th>Details</th>
</tr>
</thead>
</table>
| Inclusion criteria    | 1. Male or female aged ≥16 years  
2. Diagnosis of advanced incurable cancer (locally advanced or metastatic)  
Experiencing cancer-related pain (tumour or treatment related) with a pain score of ≥4 on the ‘average pain’ item of the Brief Pain Inventory  
3. Has the potential to benefit from pain management  
4. Expected prognosis of ≥12 weeks  
5. Living at home  
6. The patient is living in the local catchment area for a participating hospice  
7. The patient is able and willing to provide written informed consent |
| Exclusion criteria    | 1. Patients who are currently receiving or have previously received community palliative care support  
2. The patient has insufficient literacy, or proficiency in English to contribute to the data collection required for the research  
3. Patients will be excluded if they lack capacity to provide informed consent to this trial  
4. Patients with dominant chronic pain that is not cancer related (tumour or treatment) |
Table 2  Overview of trial intervention components

<table>
<thead>
<tr>
<th>Intervention components</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usual care (received by both groups)</td>
<td><strong>Referral to community palliative care:</strong> Screening of patients with pain from advanced cancer will be implemented by optimising entry points to the care pathway via oncology (or related) outpatient services and will facilitate the flow of patients to appropriate pain support and when required. Oncology research nurses will refer trial participants to the local community palliative care team at which point the locally assigned palliative are nurse will endeavour to arrange an initial visit/appointment with participant within 1 week of randomisation. <strong>Appointment into palliative care:</strong> This will take place by a locally assigned community palliative care nurse. Routine practice will be followed, including an assessment of the participants’ other palliative care needs. For those participants allocated to receive usual care and supported self-management, the nurse will be trained in the trial interventions and will introduce and deliver the trial interventions described below, alongside their usual care.</td>
</tr>
</tbody>
</table>
| Patient self-management educational intervention | **Name:** ‘Tackling Cancer Pain—A toolkit for patients and families’  
**Why:** ‘Tackling Cancer Pain—A toolkit for patients and families’ is based on a review of current evidence and on focus group interviews with patients, family caregivers and health professionals working in specialist palliative care.36,37 Providing information to patients with cancer pain and addressing concerns regarding pain and analgesia are effective interventions that support self-management and lead to improvements in pain outcomes.18–22  
**What:** ‘Tackling Cancer Pain—A toolkit for patients and families’ is formatted as a loose-leaf ring binder with an accompanying DVD. It consists of five sections: Understanding Cancer Pain; Using Drugs to Manage Pain; Additional Approaches to Managing Pain; Talking About Pain; Getting More Help. Each section contains information and self-directed learning activities along with sources of further information. It is written in easily understandable lay persons’ language. The booklet and DVD contain essentially the same information but in different formats and are structured so that they can be used independently by patients or family members. Guidance is given in each chapter about how to use the information presented. Step-by-step tuition is provided on non-pharmacological pain relief measures such as relaxation and visualisation, and on how to initiate and conduct conversations about pain with health professionals.  
**Who provides:** ‘Tackling Cancer Pain—A toolkit for patients and families’ will be introduced to participants by their trained locally assigned community palliative care nurse within 1 week of randomisation and subsequent participant questions on the booklet and DVD can be addressed to this palliative care nurse. Training on the content and use of ‘Tackling Cancer Pain—A toolkit for patients and families’ will be provided by the trial researchers. The training will include written instructions on how to train participants in the interventions and a contact for any future queries.  
**Where:** ‘Tackling Cancer Pain—A toolkit for patients and families’ is accessed by the patient or their family by reviewing the information contained in the loose-leaf ring binder and on the accompanying DVD.  
**When and how much:** Participants are not provided with details of schedule, duration, intensity or dose for using ‘Tackling Cancer Pain—A toolkit for patients and families’. Instead, participants are free to use the resource as they would like.  
**Modifications:** On-going |

**How well (planned):** Intervention data collection (baseline) will identify that the patient received the intervention. Semistructured end-of-trial interviews with patients and health professionals will also inform how the intervention is used.  
**How well (actual):** On-going

Continued
<table>
<thead>
<tr>
<th>Intervention components</th>
<th>Description</th>
</tr>
</thead>
</table>
| **e-Health intervention for routine pain assessment and monitoring in patients with advanced cancer** | **Name:** ‘PainCheck’  
**Why:** The process of assessing pain and presenting data to physicians prior to consultation, who then use it within discussions, significantly improves pain outcomes and quality of life for patients. PainCheck was developed to facilitate this communication by enabling patients to routinely report and share pain data for health professionals to access. Its development was informed by patient, caregiver and health professional involvement.  
Patients are asked about pain management techniques, which of these were helpful and how likely they are to try them in the future. Various question response options are used including multiple choice, numerical (0-10 or 0-6) slider scales and free text. After completion, patients are provided with a summary of their results and suggestions of pain management techniques they may want to try in the future. Health professionals can log in to PainCheck and view all patients registered on PainCheck and see who have completed reports. They are then able to select a patient and view responses to individual questions. Health professionals are presented with a graph that tracks patients’ current pain and pain in the last 12 hours over time. Patients are given a ‘red flag’ in the health professional system if they reach certain thresholds for current pain and pain control. After reading the patient report, health professionals can decide what action, if any, they would like to take as a result. Health professionals have the option to contact patients through PainCheck to provide information and advice. PainCheck was developed using QTool. QTool is a secure online system, which can be integrated in real time with the electronic patient record, enabling collection of patient-reported information (such as symptoms, treatment side effects, pre-clinic questions, satisfaction surveys). QTool was developed by the collaborative efforts of multiple research groups based at the University of Leeds pooling approximately £400,000 of research funding.  
Who provides: PainCheck will be introduced to participants by their locally assigned community palliative care nurse within 1 week of randomisation. Training on using PainCheck with patients will be provided by trial researchers to community palliative care nurses. Training will include instructions for training the participants in the interventions, which will include a demonstration for the participant on how to log on and use the Routine Pain Assessment and Monitoring system at the initial visit. How: PainCheck will be introduced to patients by their locally assigned community palliative care nurse. The introduction will involve participants logging in to the system (using unique login details that will be provided by the community palliative care nurse) and working through an assessment using the instruction leaflet as a guide. The palliative care nurse will oversee the participant’s first access and use of PainCheck and will provide additional support/guidance if necessary. At induction into the system, participants will be made aware that PainCheck should not be used to request urgent or emergency help; where urgent or emergency help is required participants are told to contact the emergency services. On visiting PainCheck, participants are reminded, by use of an on-screen message, that they should seek immediate medical attention should they feel the need for urgent medical advice. They are advised to contact their doctor, nurse or pharmacist. This reminder is provided near the beginning and at the end of each PainCheck session. Following an introduction to PainCheck, participants (or a person submitting responses on a participant’s behalf) will be expected to complete pain assessments without the community palliative care nurse present. Each pain assessment asks for clarification of who is entering data (ie, a patient, or someone on their behalf), which is reflected in reports when viewed by health professionals. Based on reports submitted by participants, the PainCheck system can provide two types of email alert to health professionals: high priority (generated immediately when a patient submits a report indicating high pain and/or low levels of control) and low priority (a weekly email sent when participants are interacting with PainCheck but reporting very low levels of pain or no pain). After reviewing reports submitted to PainCheck, a health professional is asked to record in the system what action they took: (1) no further action, (2) contact another health professional, (3) contact the patient and (4) other. PainCheck can be accessed by patients and health professionals using any device that enables access to the internet (eg, using laptop, smartphone or tablet computers).  
Where: The expectation is that PainCheck will be accessed by patients or their families while in the community setting, which could include usual place of residence or alternative chosen location.  
When and how much: Following the introduction of routine completion of PainCheck in the community, participants will be encouraged to use the system at least once a day, with additional entries being encouraged when/if pain events occur. PainCheck will be available to participants until 14 days after their 12-week follow-up assessment. Participants are notified in writing that access to PainCheck will be ending.  
Modifications: On-going  
How well (planned): Intervention data collection (at baseline) will confirm that a patient received details to access PainCheck. Data captured by PainCheck will provide insight into the frequency of use by patients, alongside identifying interaction between health professionals and patients that occurs through PainCheck (ie, messages sent to patients by health professionals). Semistructured end-of-trial interviews with patients and health professionals will inform how the intervention is used.  
How well (actual): On-going |
**Measuring adherence to the interventions**

We will record steps taken to ensure consistency in the delivery of the interventions—including training sessions with palliative care nurses such as additional training on delivery of the routine pain assessment and monitoring intervention for new staff. Monitoring adherence to the educational and routine pain assessment and monitoring interventions will involve the participants, the locally assigned community palliative care nurse and information directly from the routine pain assessment and monitoring tool.

**Contamination**

The risk of contamination between the two trial arms will be minimal as the educational intervention and routine pain monitoring will be made available only to participants allocated to the supported self-management arm of the trial, and there is little opportunity for participants in either trial arms to meet and discuss treatment. The importance of contamination was included in site training, so site teams are made aware not to share materials. We will record the number of contacts in community palliative care and the staff involved in the care to explore the potential for contamination. The number of Tackling Cancer Pain booklets and accompanying DVDs provided to each hospice will be monitored against the number of participants allocated to receive this intervention to ensure these are not being used for other patients. The online pain monitoring system can only be used by participants allocated to the intervention who are assigned a trial specific username and password obtained from the research team. There is no risk of contamination in the recruiting clinics as intervention delivery takes place in the community palliative care setting; notification of trial referrals to the palliative care team will clearly document the participants’ randomisation allocation. We will monitor the timing at which patients are referred into palliative care and documentation of previous palliative care discussions.

**Assessments and data collection**

Required data, assessment tools, collection time points and processes are summarised in table 3 and detailed further in online supplementary appendix 1.

**Clinical data**

Clinical follow-up data will be obtained directly from participant’s hospital and palliative care records by the research nurse and palliative care team up to 12 weeks post-randomisation. Data recorded will include healthcare use, including referral and contacts with community palliative care, hospital attendances and admissions, prescription medication use and use of pain relief, and related unexpected serious adverse events. All-cause mortality will be collected continuously throughout the trial up until the point of the final participant’s 12-week follow-up assessment. Details of participants and health professional’s use of PainCheck will be obtained directly from the PainCheck system via an export into Microsoft Excel in comma separated values (CSV) format.

**Participant-completed data**

Patient-reported outcome measures are collected via post at 6 and 12 weeks following randomisation. Where required, the trial researcher will collect this data by telephone.

Participant questionnaires are posted at weeks 5 and 11 for each follow-up time point, following which the trial researcher will contact the participant by telephone to check receipt and offer completion of the questionnaires over the phone if the participant wishes to do so. If the questionnaire pack is not completed over the phone, and questionnaires are not returned by post 1 week later, the trial researcher will telephone the participant again to remind them. If contact cannot be made, the trial researcher will continue to attempt to contact the participants up to weeks 8 and 14 for each follow-up time point. If the trial researcher becomes unblinded to treatment allocation, this will be recorded and the subsequent follow-up telephone call at 12 weeks will be conducted by an alternative researcher.

Prior to contacting the participant for the follow-up visits or to post the questionnaires, the participants’ survival status will be established by the central research team via the general practitioner or the oncology research nurse.

At the end of the 12-week follow-up period, participants will receive a thank you letter through the post (along with their 12-week questionnaires).

**Qualitative interviews**

A subsample of 15 consenting usual care plus supported self-management arm participants will be invited to take part in a semi-structured interview at approximately 6 or 12 weeks post-randomisation. The interview will explore what participants felt about referral to community palliative care, how they used the Tackling Cancer Pain booklet/DVD and PainCheck, and if they found the interventions useful. A proportion of participants will be interviewed at 6 weeks to ensure a representative sample considering loss to follow-up for illness or death by 12 weeks. Participants will be selected based on their age, gender, community palliative care team (hospice) and level of PainCheck use.

A sample of 15 palliative care nurses will be invited to take part in a semi-structured end-of-trial interview in order to explore their thoughts on the interventions, if they found the interventions useful, how the interventions impacted on pain management and their clinical practice, and potential within-trial contamination. Nurses will be asked to sign a consent form before the interview begins and will be selected based on their team (hospice), level of PainCheck use and the number of trial participants they have seen.

Both interviews will be conducted by a different trial researcher to that involved in other data collection, will last approximately 60 min and will be audio-recorded and transcribed verbatim.
Health service delivery data
For all participating sites, the central research team will collect details of current service provision to help understand the local services and standard care pathways for the study population. This will include data collection to explore who is responsible for identifying patients as requiring pain management support and/or a referral to palliative care, who is responsible for performing referrals and how closely the oncology (or related) clinic staff work with their hospital and local community palliative care teams.

Table 3 Summary of assessment type, completers and timing

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Who to complete/action</th>
<th>Timeline (weeks post-randomisation)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Screening</td>
</tr>
<tr>
<td>Baseline data (collected from case notes)</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>Demographic data, eligibility, written informed consent</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>Background and medical history</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>Referral to local participating community palliative care team</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>Schedule initial appointment within 1 week; deliver usual care or usual care and introduction of trial interventions as determined by randomisation allocation</td>
<td>Palliative care team</td>
<td>X</td>
</tr>
<tr>
<td>Clinical follow-up data (collected from case notes or hospice system for example, SystmOne)</td>
<td>Palliative care team</td>
<td>X</td>
</tr>
<tr>
<td>Use of Intervention and usual care details</td>
<td>Palliative care team</td>
<td>X</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Palliative care team</td>
<td>X</td>
</tr>
<tr>
<td>Serious adverse event reporting</td>
<td>Palliative care team</td>
<td>Ongoing reporting</td>
</tr>
<tr>
<td>Clinical follow-up data (collected from case notes, hospital system for example, SystmOne and PPM database)</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>Healthcare use</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>Pain medication</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>Date of referral to community palliative care, no and details of contacts</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Research nurse</td>
<td>X</td>
</tr>
<tr>
<td>Serious adverse event reporting</td>
<td>Research nurse</td>
<td>Ongoing reporting</td>
</tr>
<tr>
<td>Patient-completed questionnaires (completed in clinic at baseline and at home/over telephone for follow-up visits)</td>
<td>Research nurse</td>
<td>Ongoing reporting</td>
</tr>
<tr>
<td>BPI assessment</td>
<td>Trial researcher</td>
<td>X</td>
</tr>
<tr>
<td>7-point global rating change of pain</td>
<td>Trial researcher</td>
<td>X</td>
</tr>
<tr>
<td>Healthcare use (Health Economics questionnaire)</td>
<td>Trial researcher</td>
<td>X</td>
</tr>
<tr>
<td>Patient Pain Questionnaire</td>
<td>Trial researcher</td>
<td>X</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>Trial researcher</td>
<td>X</td>
</tr>
<tr>
<td>EORTC QLQ-C30</td>
<td>Trial researcher</td>
<td>X</td>
</tr>
<tr>
<td>Clinical follow-up data (collected via GP practice)</td>
<td>Trial researcher</td>
<td>Ongoing reporting</td>
</tr>
<tr>
<td>Date of referral to community palliative care</td>
<td>Trial researcher</td>
<td>Ongoing reporting</td>
</tr>
<tr>
<td>Survival status</td>
<td>Trial researcher/Leeds Institute of Clinical Trials Research</td>
<td>Ongoing reporting</td>
</tr>
<tr>
<td>Routine monitoring data</td>
<td>Trial researcher*</td>
<td>Ongoing reporting</td>
</tr>
<tr>
<td>Uptake (patients and palliative care nurse) and patient-reported pain diaries</td>
<td>Trial researcher*</td>
<td>~6 or 12 weeks post-randomisation</td>
</tr>
<tr>
<td>Qualitative participant interviews</td>
<td>Trial researcher*</td>
<td>End of trial</td>
</tr>
<tr>
<td>Participant qualitative palliative care nurse end of trial interviews</td>
<td>Trial researcher*</td>
<td></td>
</tr>
</tbody>
</table>

*BPI, Brief Pain Inventory; EORTC, European Organization for Research and Treatment of Cancer; GP, general practitioner.
Sample size
To address the potential effectiveness of the intervention, the power calculation is based on the difference in mean pain severity (BPI) at 12 weeks. With 80% power and a two-sided type I error rate of 0.05, we estimate that 128 patients (64 per group) will be required to detect a moderate intervention effect size of 0.5\(^2\) between the intervention and control arm. In addition, a relative reduction of ≥30% in pain severity (BPI) is an accepted threshold for clinically significant improvement in pain trials.\(^3\) Results from a previous study involving automated symptom modelling found a 27% difference in such improvement rates at 12 weeks.\(^2\) Our estimated sample size will therefore also provide 80% power to detect a similar difference in rate. As our patient sample is drawn from a generally frail population, we have allowed for an attrition rate of 20% and therefore aim to recruit 160 participants (80 per group). The trial is expected to recruit from four to five participating centres that will be selected due to their large oncology (or related) clinics.

Data analysis
There are no planned interim analyses; outcome data will be analysed once only. All analyses will be conducted on the intent-to-treat population, in which all participants will be included in the analysis according to allocation, regardless of non-compliance with the intervention. An overall two-sided 5% significance level will be used for all statistical endpoint comparisons. Details of all analysis are provided in box 1.

PATIENT AND PUBLIC INVOLVEMENT
The IMPACCT research programme comprises four work streams. The first three work streams, running in parallel, sought to understand and improve current cancer pain management at the levels of the patient and their caregiver, health professional and healthcare system. Across these three work streams, extensive user engagement with patients, caregivers and health professionals occurred, informing an understanding of their priorities, experience and preferences relating to cancer pain management. Part of this work involved the development and piloting of interventions used in the trial, including assessment of their acceptability, and informed the design of the trial, its research question and outcome measures. The research programme also has a patient and public involvement (PPI) group, comprising patients with cancer and caregivers of those with cancer. PPI representatives are co-investigators on the research programme, contributors at all quarterly programme management meetings and members of the trial steering group. The latter enabled PPI representatives to inform the recruitment processes and conduct of the trial. For example, it was decided that due to participants having advanced disease, information sheets should provide contact details to enquire about study findings rather than active dissemination by the research team. PPI involvement has been

Box 1 Data analysis plan for primary and secondary outcomes, health economic analysis and qualitative data

Analysis activities
Primary outcomes
► To assess the primary implementation outcome, the proportion of participants receiving each intervention, at least one intervention and all interventions will be summarised overall and by recruiting site along with 95% CIs.
► To assess the primary effectiveness outcome, pain severity (Brief Pain Inventory, BPI), we will fit a linear mixed-effects regression model with repeated measures (6 and 12 weeks). The model will contain centre random effect, and fixed effects for intervention group, research centre, baseline score, time, and intervention group by time interaction. Similarly, a logistic mixed-effects regression model will be used to assess the proportion of participants with ≥30% reduction in pain severity.

Secondary outcomes
► The secondary outcomes BPI interference, participant’s pain knowledge and experience, EQ-5D and European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 will be assessed using a linear mixed-effects regression model with repeated measures as per the primary outcome.
► The 7-point global rating of change in pain, healthcare use and safety data will be summarised.
► Exploratory subgroup analysis will be conducted, differentiating participants in the intervention arm who were engaged in the use of PainCheck versus those who were not. Descriptive statistics will be used to present the primary outcome at each time point for each subgroup.

Missing data
► Reasons for attrition and missing data will be summarised along with reason, following the classification set out in the MORECare statement:\(^4\) attrition due to death, illness or at random; with additional reason due to participant withdrawal.
► The pattern of missing data according to participant characteristics will be investigated to inform the multiple imputation approach and the assumptions of Missing At Random and Missing Not At Random.
► Regression analysis will handle missing data due to attrition by testing results from different methods of imputation, including multiple imputation\(^5\) in the primary analysis, allowing all participants in the intention-to-treat population to be included, and analysis to the availability of data in sensitivity analysis. This will allow us to test the trial conclusions under different assumptions and biases introduced through missing data.

Health economic analysis
► The economic evaluation will follow the National Institute for Health and Care Excellence reference case\(^6\) and hence will be a cost-utility analysis presenting cost per incremental quality-adjusted life year (QALY) from the perspective of the healthcare and personal social services provider. It will be informed by earlier work of the research team.\(^6\)
► The evaluation will combine trial-based and model-based analyses. Trial data will be analysed to yield within-trial cost-utility results. Participants will complete the utility measures (EQ-5D and EORTC-8D), the latter derived from the QLQ-C30\(^7\) at baseline and follow-up along with a resource use questionnaire. The EQ-5D values will be used in the primary analysis with supplementary analyses presented based on the EORTC-8D and pain rating item from the BPI. Survival data will be combined with utility data to calculate QALYs and resource use costs using national resources (eg, National...
central to all research programme activities, informing our approach to patient, caregiver and health professional engagement prior to and during the trial.

DISCUSSION

This trial will conclude a 5-year programme of research funded by the NIHR PGfAR Programme. The wider aim of the programme, IMPACT, is to reduce distress from cancer pain in palliative care patients and reduce the impact on the NHS of avoidable admissions for cancer pain. We believe that our RCT has the potential to significantly influence NHS service delivery to community-based patients with pain from advanced cancer. We aim to provide definitive evidence of whether two simple interventions delivered by community palliative care nurse in palliative care that support self-management are clinically and cost-effective additions to standard community palliative care. We are conducting a detailed process evaluation that will inform an implementation strategy for the wider NHS if we find a benefit for intervention. One of our interventions, ‘Tackling Cancer Pain—A toolkit for patients and families’ addresses all the information recommendations in the National Institute for Health and Care Excellence guidance on ‘Opioids in Palliative Care’ and was runner-up in the British Medical Association Patient Education awards 2016. Our electronic pain monitoring system ‘PainCheck’ is underpinned by significant development work,31–35 which explores engagement by patient and healthcare professionals. PainCheck offers a potentially time-efficient and cost-efficient way for busy community palliative care teams to monitor patients with cancer pain and respond when needed.

**Box 1 Continued**

| Health Service reference costs, personal social services research unit costs. The development and implementation of the interventions will be costed following consultation with the trial researchers leading each Improving the Management of Pain from Advanced Cancer in the Community programme work stream. The within-trial analysis will present (where appropriate) incremental cost-effectiveness ratios (ICERs) for the interventions versus usual care with ICERs below £20 000 usually indicative of cost-effectiveness. Non-parametric bootstrapping and deterministic sensitivity analyses will be conducted to estimate the level of uncertainty around the ICERs.
| In parallel, a simple decision-analytic Markov model will be developed. This will be developed according to best practice46 and yield cost per QALY estimates. The model will allow the extrapolation of expected costs and benefits beyond the trial period. It will also allow a more in-depth exploration of uncertainty in the ICERs and a more flexible exploration of scenario sensitivity analyses.
| 

**Process evaluation**

- Quantitative analysis will summarise delivery and implementation of the intervention according to:
  - Palliative care nurse use of interventions, including the number of participants seen by each palliative care nurse by trial arm to explore the level of clustering and potential for contamination by the nurse.
  - Training and supervision for intervention delivery.
  - Participant uptake, including a flow diagram to depict uptake and usage according to the initial palliative care visit and subsequent use of PainCheck.

- Qualitative interview analysis: Interview transcripts will be analysed using framework analysis49 to draw out key themes from the data. The framework analysis process involves five key stages: (1) Familiarisation—getting an overview of the issues raised during the interviews; (2) Identifying a thematic framework—making notes on the key issues discussed; (3) Indexing—applying the thematic framework to the data; (4) Charting—moving data from individual interviews and putting sections into the framework; (5) Mapping and interpretation—the researcher attempts to make sense of the data and interpret the key themes and issues discussed.

**Ethics and dissemination**

A favourable ethical opinion was obtained from the NHS National Research Ethics Service Committee Yorkshire & The Humber—Leeds East, reference number 15/YH/0235. The trial opened and recruited the first participant in October 2015. Screening, recruitment and implementation were monitored on a monthly basis. After 6 months of recruitment and after 13 patients had been recruited, it was apparent that the trial design needed to be changed to ensure the trial is embedded in existing NHS care pathways. A substantial amendment was made to remove the concept of ‘early screening and referral’ to allow identification at point of referral. The rationale for this was that patients were already being referred to community palliative care services for pain management support when needed. The trial is sponsored by the University of Leeds (Faculty Head of Research and Innovation Support, Faculty of Medicine and Health Research Office, University of Leeds), managed by the Clinical Trials Research Unit at the University of Leeds and supported by a Trial Management Group (TMG) and Trial Steering Committee (TSC). The TMG is composed of individuals responsible for the day-to-day management of the trial, including the PI (MIB), statisticians, trial manager, research nurse and researchers. The TSC includes external experts who will provide overall supervision for a trial on behalf of the Trial Sponsor and Trial Funder.

The following organisations have given research governance approval for the trial: Diana Princess of Wales Hospital, Grimsby; Care Plus Group, Grimsby; Nottingham City Hospital, Nottingham; Nottingham Citycare, Nottingham; St James University Hospital, Leeds; St Gemma’s Hospice, Leeds; Wheatfields Hospice, Leeds; Wakefield Hospice, Wakefield; York Hospital, York; St Leonards Hospice, York; Bradford Royal Infirmary, Bradford; Marie Curie Hospice, Bradford; Huddersfield Royal Infirmary, Huddersfield; Kirkwood Hospice, Huddersfield; Churchill Hospital, Oxford; Sobell House, Oxford; Scarborough General Hospital, Scarborough; St Catherine’s Hospice, Scarborough.

Data will be collected and retained in accordance with the Data Protection Act 1998 (and successor legislation). Trial documents (paper and electronic) will be retained in a secure location for 5 years after trial completion. To support dissemination of our findings, we will work...
with local and national patient advocacy groups (linking to public and patient involvement co-applicants on the wider programme) to explain our work and encourage wider adoption of our findings. We will also disseminate through academic papers and presentation at national and international clinical meetings.

Author affiliations

1. Academic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
2. Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
3. Leeds Community Healthcare NHS Trust, Leeds, UK
4. Division of Psychological and Social Medicine, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
5. Academic Unit of Palliative Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
6. School of Healthcare, Baines Wing, University of Leeds, Leeds, UK
7. Department of Health Sciences, University of York, Heslington, UK

Acknowledgements

We thank our patient and public involvement representatives for their contribution throughout all stages of the research programme. We also thank members of the trial steering committee (Dr Barry Laird, Dr Wei Gao, Dr Sheila E Fisher) and the wider programme management group (Professor Alison Blenkinsopp, Mary Godfrey, Professor Robbie Foy, Professor Sue Pavitt, Dr Geoff Hall, Professor Richard Jones, Christine Allmark, Peter Rainey, Zoe Edwards, and Karen Vinal-Collier).

Contributors

MJA, AWH and MF drafted the initial manuscript. All authors reviewed the manuscript prior to submission. All authors were involved in the critical revision of the article for important intellectual content and provided final approval of its content. The team comprises the primary investigator (MIB) and co-investigators (LEZ, BMB, SJC, CH, KF, JMB) of the larger research programme. The team includes a trial statistician (AWH), trial coordinator (MF), trial management lead (SH), health economic lead (OM, JOD) and lead research nurse (KD). Members of the research team also led the design, development and evaluation of the patient self-management educational intervention (JH, NDH, KF) and the ehealth intervention for routine pain assessment and monitoring in patients with advanced cancer (BMB, MJA, ST, JH).

Funding

This article presents independent research funded by the National Institute for Health Research (NIHR) Programme Grant (RP-PG-0610-10114).

Disclaimer

The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. The sponsors and funders had no involvement in the study design; collection, management, analysis and interpretation of data; writing of the report; and the decision to submit the report for publication.

Competing interests

None declared.

Patient consent

Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

Ethics approval

Ethical approval was obtained from the Yorkshire & The Humber—Leeds East Research Ethics Committee (reference: 15/YH/0235).

Provenance and peer review

Not commissioned; peer reviewed for ethical and funding approval prior to submission.

Data sharing statement

No additional data available.

Author note

Trial registration number: ISRCTN18281271. The trial was added to the ISRCTN registry on 30 September 2015.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


